Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cystic Fibrosis, Oncology, and Neurodegeneration Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AHSA1 (AHA1) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | AHSA1 Recombinant / Mutant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Intracellular expression or E. coli derived. | View AHSA1 Products |
| Domain Mapping | AHSA1-DP2 (HSP90 Binding Domain) Protein. Residues 240-348, HEK293 Expressed. For PPI disruption assays. | View AHSA1 Products |
| Gene Delivery | AHSA1 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines and cellular chaperone assays. | View AHSA1 Products |
| Benchmark Ab | Anti-AHSA1 Recombinant Antibody. Recombinant positive control for target engagement and Western Blot assays. | View AHSA1 Products |
| Validator | AHSA1 siRNA Set. For knockdown verification and phenotypic baseline establishment. | View AHSA1 Products |
| Related Target A | HSP90AA1. Direct binding partner; essential for AHSA1-HSP90 ATPase modulation assays. | View HSP90AA1 Products |
| Related Target B | CFTR. Downstream client protein; folding and membrane trafficking rescued by AHSA1 inhibition. | View CFTR Products |
| Related Target C | CDC37. Competing HSP90 co-chaperone. For selectivity screening. | View CDC37 Products |
| Related Target D | STIP1 (Hop). HSP70/HSP90 organizing protein. For pathway analysis. | View STIP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| HSP90-AHSA1 PPI Disruption Screening | High Purity (>95%) tag-free or site-specifically tagged AHSA1 proteins, Theoretical MW verified by Mass Spec, ideal for SPR/BLI. |
| Intracellular Target Validation | Sequence-verified Lentivirus for stable over-expression, enabling high-throughput cellular screening. |
| Lack of Reliable Detection Controls | Recombinant anti-AHSA1 antibodies with stringent quality control, eliminating batch-to-batch variation. |
| Phenotypic False Positives | Validated siRNA sets included for orthogonal specificity and target knockdown checks. |
| Domain-Specific Binding Mapping | Isolated DP1 (dimerization) and DP2 (HSP90-binding) domain proteins available for epitope binning. |
| Selectivity vs. Other Co-chaperones | Homolog panel: CDC37, STIP1, FKBP4 proteins strictly verified by Mass Spec for counter-screening. |
| Cellular Thermal Shift Assay (CETSA) | High-concentration stable proteins (up to 5 mg/mL) for biophysical validation. |
Live AHSA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for AHSA1 (Activator of 90 kDa heat shock protein ATPase homolog 1) modulators is intensifying, particularly in the fields of cystic fibrosis (CF) and oncology. As a critical co-chaperone that accelerates the ATPase activity of HSP90, AHSA1 dictates the folding trajectory of numerous client proteins. Major players are shifting focus from direct, often toxic, pan-HSP90 inhibitors to small molecule PPI (Protein-Protein Interaction) inhibitors that selectively disrupt the AHSA1-HSP90 complex. As first-generation therapies reach pre-clinical and early clinical milestones, the next wave of R&D is targeting allosteric modulation and AHSA1-targeted PROTACs to precisely control mutant CFTR trafficking and mutant p53 degradation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic Consortia, Rare Disease Biotechs | Cystic Fibrosis, Solid Tumors | PPI Selectivity Assay (Need High-Purity Recombinant AHSA1 and HSP90) |
| Peptide Disruptor | Biotech Startups | Solid Tumors | Competition Binding Assay (Need isolated DP2 domain) |
| PROTACs / Degraders | Emerging Targeted Degradation Cos. | Neurodegeneration (Tauopathies), Refractory Cancers | Ternary Complex Formation (Need heavily QC'd proteins for SPR) |
| Gene Therapy / RNAi | Preclinical Gene Editing Biotechs | Refractory Cancers | Knockdown Validation (Need standardized siRNA and Lentivirus tools) |